Fact-checked by Grok 2 weeks ago

Sublingual administration

Sublingual administration is a route of drug delivery in which a medication is placed under the tongue, where it dissolves in saliva and is absorbed directly into the bloodstream through the highly vascularized sublingual mucosa.^[1] This method enables rapid onset of therapeutic effects by bypassing the gastrointestinal tract and hepatic first-pass metabolism, which can degrade or inactivate many drugs.^[2] Sublingual delivery gained early prominence in the late 19th century with nitroglycerin for angina relief and further expanded in the mid-20th century starting in the 1950s with the use of steroids such as methyltestosterone.^[3]^[4] Key advantages include enhanced bioavailability for lipophilic, low-molecular-weight drugs, ease of administration without water, and suitability for patients with swallowing difficulties, such as children or the elderly. Absorption occurs primarily via passive diffusion across the thin epithelial layer, influenced by factors like drug solubility in saliva and pH. Common applications encompass emergency treatments and chronic conditions, with notable examples including nitroglycerin for acute angina, buprenorphine for opioid dependence, fentanyl for breakthrough cancer pain, and misoprostol for labor induction.^[1] While effective, limitations such as restricted surface area for dosing and potential taste or irritation issues constrain its use to potent, fast-acting medications rather than sustained-release therapies.

Overview

Definition and Principle

Sublingual administration is a route of drug delivery in which a medication is placed under the tongue, allowing it to be absorbed directly through the highly permeable oral mucosa into the systemic bloodstream.^[5] This method leverages the anatomical advantages of the sublingual region to achieve rapid onset of action without requiring swallowing.^[6] The underlying principle involves the dissolution of the drug in saliva, followed by passive diffusion across the sublingual epithelium into the underlying capillaries.^[7] The sublingual veins drain directly into the superior vena cava, thereby circumventing the hepatic first-pass metabolism that occurs with traditional oral ingestion.^[7] This venous pathway ensures that the drug enters the systemic circulation more efficiently, avoiding significant degradation in the gastrointestinal tract.^[5] Key anatomical features of the sublingual mucosa contribute to its suitability for absorption, including its high vascularity, which provides a rich network of blood vessels for rapid uptake.^[1] The epithelium is notably thin, with a thickness of 100–200 micrometers, enabling easier permeation by lipophilic or small-molecule drugs.^[1] Additionally, the neutral pH of the sublingual environment, ranging from approximately 6.2 to 7.4, supports drug stability and ionization favorable for absorption.^[7]

Historical Development

The practice of sublingual administration traces its roots to ancient traditional medicine systems, where herbal remedies were placed under the tongue for rapid absorption and therapeutic effects. In Unani medicine, a Greco-Arabic system with origins dating back over 2,000 years, sublingual delivery was employed for managing acute conditions such as cardiac emergencies and hypertension through dissolvable tablets or pills held beneath the tongue.^[8] Similar approaches appear in broader ancient practices, including the placement of herbal substances in the oral cavity in Ayurvedic and traditional Chinese medicine to bypass digestive barriers and achieve swift systemic action, though documentation is often embedded in oral traditions rather than written records.^[9] The modern pharmaceutical adoption of sublingual administration began in the 19th century with the treatment of angina pectoris. In 1867, Scottish physician Thomas Lauder Brunton introduced amyl nitrite inhalation as a vasodilator to alleviate chest pain, marking an early recognition of the route's potential for rapid onset in acute cardiovascular conditions.^[10] This was followed in 1879 by English pharmacologist William Murrell, who popularized sublingual nitroglycerin—administered as drops under the tongue—for angina relief, demonstrating its efficacy in dilating coronary vessels and establishing it as a cornerstone of emergency therapy.^[11] Murrell's work, building on Brunton's, highlighted the route's ability to avoid first-pass metabolism, influencing subsequent developments in cardiovascular pharmacology. Key advancements in the early 20th century included the formulation of stable sublingual nitroglycerin tablets, which improved dosing precision and portability compared to liquid forms, enabling widespread clinical use by the 1920s.^[12] Expansion into hormone therapies occurred in the mid-20th century, with sublingual progesterone tablets emerging in the 1940s and 1950s to enhance bioavailability for gynecological applications, reflecting growing interest in mucosal routes for labile compounds. The 1970s saw buprenorphine become available worldwide as a sublingual analgesic, with approvals for opioid dependence following in the late 1990s (e.g., high-dose formulations in Europe) and 2002 in the US, offering partial agonist effects with reduced abuse potential.^[13] Regulatory milestones in the 2000s advanced sublingual applications beyond small molecules, with the U.S. FDA approving the first sublingual immunotherapy tablets for allergens, such as grass pollen extracts in 2014, enabling disease-modifying treatment for allergic rhinitis through standardized mucosal delivery.^[14] By 2025, sublingual delivery has expanded to include generics and novel formulations for peptides and vaccines, building on earlier immunotherapy approvals.^[15] These developments underscore the route's evolution from empirical remedies to precision-engineered therapies.

Methods and Forms

Administration Techniques

Sublingual administration begins with thorough hand washing to prevent contamination, followed by moistening the mouth with a sip of water if the medication form requires it for easier dissolution. The patient should then place the medication—whether a tablet, film, or spray—directly under the tongue, as far back as possible without chewing, swallowing, or moving it, to allow contact with the mucosal surface. The mouth should remain closed to avoid dislodging the dose.^[16]^[17]^[18] Patients are advised to sit upright or tilt the head slightly back during administration to minimize the risk of premature swallowing and enhance absorption by gravity. In emergency situations, such as an angina attack, the patient should sit down immediately upon feeling symptoms to prevent dizziness or fainting while placing the dose under the tongue. This positioning helps maintain the medication in place and supports safe delivery, particularly when rapid onset is critical.^[19]^[20] The medication is typically held under the tongue for 30 seconds to 5 minutes, depending on the specific product, until it fully dissolves; patients should avoid eating, drinking, or smoking for at least 5-10 minutes afterward to prevent interference with absorption. Proper administration may be indicated by a mild tingling or burning sensation under the tongue, which is a normal sign of mucosal contact for some drugs like nitroglycerin. Monitoring involves observing for complete dissolution and noting any immediate effects, with patients instructed to seek medical help if symptoms persist beyond the expected relief time.^[19]^[20]^[16] For pediatric patients, techniques may involve using flavored formulations to improve compliance, with caregivers assisting by gently holding the child's mouth closed until dissolution; administration should be supervised to ensure the dose remains sublingual rather than swallowed. In elderly individuals, who may have reduced saliva production or dexterity issues, moistening the mouth beforehand and allowing extra time for dissolution can aid effectiveness, especially for those with swallowing difficulties. These adjustments prioritize ease and safety without altering the core procedure.^[21]^[19] Common errors include swallowing the medication prematurely, which reduces bioavailability by routing it through the gastrointestinal tract, or chewing it, which can lead to uneven absorption or irritation. Moving the dose around the mouth or talking during dissolution may also displace it, diminishing efficacy; to avoid these, patients should be trained to keep the mouth still and follow product-specific demonstrations provided by healthcare providers.^[22]^[19]^[17]

Available Dosage Forms

Sublingual drugs are commonly formulated as tablets and lozenges, which are compressed solid dosage forms designed to disintegrate rapidly in the oral cavity for quick drug release. Tablets typically consist of the active ingredient mixed with excipients such as mannitol or cellulose derivatives, compressed into small, flat shapes that dissolve under the tongue within 1-5 minutes.^[23] For instance, nitroglycerin tablets achieve onset of action in 1-3 minutes due to their fast disintegration.^[24] Lozenges, often flavored and shaped similarly, incorporate mucoadhesive polymers like Carbopol to promote adherence and controlled dissolution, though they may dissolve more slowly than tablets for sustained exposure.^[23] Films and strips represent another solid format, comprising thin, flexible sheets of water-soluble polymers such as hydroxypropyl methylcellulose (HPMC) that disintegrate in 30 seconds to 5 minutes. These forms allow for precise dosing through uniform drug distribution across the film surface, typically accommodating 1-30 mg of active ingredient per strip. Their ease of administration without water or chewing makes them particularly advantageous for pediatric patients, reducing risks of choking and improving compliance.^[25] Liquid formulations include drops and sprays, delivered via droppers for adjustable volumes or metered spray devices for consistent aerosolization. Drops are aqueous or alcohol-based solutions placed directly under the tongue, while sprays use propellants like propylene glycol for fine mist dispersion, enabling rapid mucosal contact without the need for disintegration. These are frequently employed for allergens in sublingual immunotherapy, where small volumes of extract are administered daily.^[23]^[26] Powders and gels are less prevalent sublingual formats, with powders consisting of micronized particles often blended with mucoadhesives for better retention and controlled release upon contact with saliva. Gels, as semi-solids, utilize viscous polymers like Carbopol 934 or chitosan to form in situ structures that provide sustained drug diffusion, achieving near-complete release over 30 minutes while adhering to the mucosa.^[7]^[27] Key formulation factors across these dosage forms include excipients such as sweeteners (e.g., sucrose) and buffers to improve palatability, mask bitterness, and maintain pH stability for mucosal compatibility. Manufacturing emphasizes rapid disintegration, ideally under 30 seconds for optimal patient experience, achieved through techniques like lyophilization or superdisintegrants, ensuring the form disperses quickly in minimal saliva.^[28]^[23]

Pharmacology

Absorption and Bioavailability

Sublingual absorption primarily occurs through passive diffusion across the lipid bilayer of the sublingual epithelium, where drugs partition into and permeate the non-keratinized mucosal membrane driven by concentration gradients.^[1] This process favors lipophilic molecules that can traverse the transcellular route, with optimal permeability achieved for compounds exhibiting moderate lipophilicity (logP values of 1-3) and low molecular weight (ideally <500 Da), as higher molecular weights hinder diffusion through the tight junctions or aqueous pores.^[29] Hydrophilic drugs may utilize paracellular pathways, though this is less efficient due to the epithelium's thickness (100-200 μm).^[1] Bioavailability (F) following sublingual administration is quantified as F = (AUC_sublingual / AUC_IV) × 100%, where AUC represents the area under the plasma concentration-time curve for sublingual and intravenous routes, respectively, typically ranging from 30-90% for suitable candidates compared to <20% for some drugs via the oral route due to first-pass metabolism avoidance.^[30] This enhanced systemic exposure results from direct entry into the venous drainage of the sublingual mucosa, which feeds into the jugular vein and superior vena cava, bypassing hepatic metabolism.^[29] Several physiological factors influence sublingual absorption efficiency. Salivary flow rate, normally 0.3-0.4 mL/min unstimulated, can increase to 1-2 mL/min or higher with mechanical or gustatory stimulation, promoting drug dissolution and contact time with the mucosa.^[1]^[31] The salivary pH (typically 6.2-7.6) favors absorption of the unionized drug form, as this neutral to slightly alkaline environment minimizes ionization for weak bases and acids, enhancing lipid solubility.^[32] Variations in sublingual blood flow, which is rich due to high vascularity (up to 1 mL/min/g tissue), further accelerate uptake but can be altered by vasoconstrictors or disease states.^[29] The pharmacokinetic profile of sublingual administration features rapid onset, with peak plasma concentrations often reached in 5-15 minutes, attributed to the thin epithelium and direct systemic access.^[1] This leads to a shorter effective duration compared to oral routes, as drugs exhibit quicker distribution and potential for faster elimination without enterohepatic recirculation.^[29] Drug suitability for sublingual delivery requires low doses (<10 mg) to fit the limited mucosal surface area (~26 cm²) and chemical stability in saliva to prevent degradation by enzymes like amylase.^[1]^[33]

Advantages and Limitations

Sublingual administration offers several key advantages, particularly for drugs requiring rapid systemic effects. The route enables quick onset of action due to the thin epithelium (100–200 μm) and rich vascular supply of the sublingual mucosa, allowing drugs like nitroglycerin to provide angina relief within 2–5 minutes.^[5]^[1] It also bypasses hepatic first-pass metabolism, resulting in higher bioavailability for drugs prone to liver clearance, such as fentanyl or buprenorphine, compared to oral ingestion.^[7]^[29] As a non-invasive method, it serves as an alternative to injections, enhancing patient compliance, especially in pediatrics where needle aversion is common, and in individuals with swallowing difficulties.^[5]^[1] Despite these benefits, sublingual administration has notable limitations. The small mucosal surface area (approximately 26 cm²) restricts it to low-dose formulations, typically up to 10 mg, making it unsuitable for high-dose or large-molecule drugs like peptides and proteins.^[29]^[7]^[33] Bitter or unpleasant tastes from many formulations can cause patient discomfort and reduce adherence, while absorption variability arises from factors such as salivary flow, pH changes, food intake, or mucosal conditions.^[29]^[7] Additionally, it is ineffective for irritant substances or hydrophilic compounds due to poor permeability across the mucosal barrier.^[1] The safety profile of sublingual administration is generally favorable, with low risk of overdose owing to controlled absorption rates, though potential for local irritation or allergic reactions exists, particularly in patients with oral ulcers or xerostomia.^[29]^[1] Contraindications include active mucosal lesions, where absorption could exacerbate irritation.^[5] Compared to other routes, sublingual delivery provides faster effects than oral administration by avoiding gastrointestinal degradation and first-pass effects, yet it is slower and less precise than intravenous delivery while remaining non-invasive.^[7] Versus the buccal route, sublingual offers quicker venous drainage to the superior vena cava due to its thinner tissue, leading to more rapid systemic uptake.^[5]^[7] Recent advancements as of 2025 have addressed some limitations through taste-masking technologies in fast-dissolving films and the use of permeation enhancers like nanoparticles and mucoadhesive polymers, which improve retention, stability, and bioavailability for challenging drugs.^[1]^[7]

Clinical Applications

Psychoactive Substances

Sublingual administration is employed for several psychoactive substances, particularly in the management of opioid dependence and emerging psychiatric therapies, due to its ability to provide rapid onset and improved bioavailability compared to oral routes. Buprenorphine, a partial opioid agonist, is commonly delivered sublingually via films like Suboxone for treating opioid use disorder, with bioavailability ranging from 30% to 50%, allowing effective dosing while minimizing diversion risks through the inclusion of naloxone. In therapeutic psychiatry, sublingual delivery of psychedelics such as LSD in blotter form and psilocybin (typically oral, with emerging sublingual psilocin formulations) microdoses facilitates controlled absorption for conditions like anxiety and depression, with studies demonstrating pharmacokinetic profiles that support microdosing regimens without full hallucinogenic effects.^[34]^[35]^[36]^[37] The mechanism underlying sublingual psychoactive delivery involves direct absorption through the oral mucosa into the systemic circulation via the jugular vein, bypassing hepatic first-pass metabolism and enabling quicker crossing of the blood-brain barrier for rapid central nervous system effects. This route avoids extensive liver metabolism, which can reduce required doses by up to 50% for certain lipophilic psychoactives like buprenorphine, where oral bioavailability drops below 10%. Consequently, onset of effects occurs within minutes, contrasting with the delayed absorption of swallowed formulations.^[38]^[39] In clinical applications, sublingual buprenorphine serves as an effective alternative to methadone for opioid addiction treatment, offering flexible office-based prescribing and reduced clinic visit requirements while maintaining comparable retention rates in therapy. For mood disorders, sublingual ketamine lozenges are under investigation in trials for treatment-resistant depression and anxiety, with onset of antidepressant effects reported in 5 to 10 minutes due to mucosal absorption, providing faster relief than traditional oral antidepressants. These uses highlight sublingual routes' role in both maintenance therapy for substance use disorders and acute interventions in psychiatric care.^[40]^[41]^[42] Challenges in sublingual psychoactive administration include taste aversion, which can lead to non-adherence during long-term use of formulations like buprenorphine films, prompting patients to swallow rather than dissolve them properly. Regulatory hurdles persist for psychedelics, with MDMA-assisted therapy receiving FDA breakthrough designation in 2017 for post-traumatic stress disorder, though a 2024 rejection of its new drug application necessitated additional phase 3 trials, delaying widespread adoption of sublingual or oral analogs.^[43]^[44] Efficacy studies indicate higher adherence with sublingual opioids compared to oral forms, with retention rates in opioid use disorder treatment reaching 70% to 90% at six months, attributed to the faster onset of therapeutic effects that enhances patient satisfaction in supervised settings, though this can also increase misuse potential due to quicker euphoria.^[45]

Allergens and Immunotherapy

Sublingual immunotherapy (SLIT) utilizes standardized extracts of common environmental allergens, such as grass pollen and house dust mites, to desensitize patients with allergic rhinitis or conjunctivitis through daily sublingual administration.^[46]^[47] This approach gradually builds immune tolerance over a typical treatment duration of 3-5 years, allowing patients to experience sustained symptom relief even after discontinuation.^[48]^[49] The mechanism of SLIT involves a localized immune response in the oral mucosa, where allergen exposure promotes the induction of regulatory T-cells (Tregs) that secrete immunosuppressive cytokines like IL-10, thereby suppressing Th2-driven allergic inflammation and reducing IgE-mediated hypersensitivity reactions.^[50]^[51]^[52] Meta-analyses confirm SLIT's efficacy, demonstrating significant reductions in symptom scores and medication use, with response rates achieving up to 70% symptom improvement in allergic rhinitis patients across multiple trials.^[53]^[54] Standard SLIT protocols begin with low initial doses, often 100-300 index of reactivity (IR) units, followed by a gradual escalation over days to weeks to reach a maintenance dose, which is then administered daily for the full treatment course.^[55]^[56] Available forms include liquid drops or dissolvable tablets; for instance, Grazax, a grass pollen SLIT tablet containing 75000 SQ-T Timothy grass extract, was approved in Europe in 2006 for treating grass pollen-induced allergic rhinoconjunctivitis.^[57]^[58] Key benefits of SLIT include the convenience of home administration, which minimizes clinic visits compared to subcutaneous alternatives, and a substantially lower risk of severe adverse events, with anaphylaxis extremely rare in SLIT (fewer than 1 case per 100 million doses) versus higher rates of systemic reactions (up to 0.8%, including rare anaphylaxis) in subcutaneous immunotherapy.^[59]^[60]^[61]^[62] Recent developments as of 2025 include expanded pediatric approvals for SLIT products, such as the FDA extension of Odactra (house dust mite SLIT tablet) to children aged 5-11 years (approved February 2025), enabling earlier intervention from around age 5; ongoing trials are also exploring multi-allergen SLIT formulations to address polysensitization, though efficacy for combined extracts remains under evaluation due to mucosal absorption limits.^[63]^[64]^[65]^[66]

Therapeutic Peptides and Proteins

Therapeutic peptides and proteins, typically exceeding 1000 Da in molecular weight, face substantial barriers to sublingual administration due to their large size, hydrophilicity, and susceptibility to enzymatic degradation by salivary proteases. These properties hinder passive diffusion across the sublingual epithelium and necessitate formulation strategies like permeation enhancers, like chitosan, which improve mucoadhesion and transiently open tight junctions to enhance paracellular transport.^[67]^[68] A representative example is desmopressin, a synthetic vasopressin analog used in diabetes insipidus, available as a sublingual lyophilisate with an absolute bioavailability of approximately 0.25%, outperforming traditional oral tablets (0.08-0.16%) but remaining lower than intranasal routes (3-10%). Experimental sublingual insulin formulations, such as nanoparticle-loaded films with enhancers like nicotinamide, have demonstrated pharmacological availability exceeding 100% and bioavailability over 80% in preclinical rodent models, though human clinical data remain limited.^[69]^[70]^[71] Advances in peptide engineering, including cyclization to reduce enzymatic cleavage at termini and PEGylation to shield hydrophilic regions and prolong mucosal residence, have bolstered stability for sublingual delivery. For instance, ongoing developments for GLP-1 receptor agonists like semaglutide include sublingual thin films and formulations in early clinical stages, aiming for phase II evaluation by 2026, with preclinical data showing 6-7% bioavailability in human volunteers for similar peptide systems.^[67]^[23]^[72] Small peptides delivered sublingually exhibit onset of action comparable to subcutaneous injection, often within 15-30 minutes, while larger proteins lag due to slower absorption kinetics. Patient adherence favors these non-injectable options for chronic conditions, reducing needle phobia and injection-site reactions.^[73]^[74] Despite these progresses, sublingual peptide and protein therapeutics remain an emerging field with less than 5% market share compared to injectable biologics, primarily due to inconsistent bioavailability (often <10%) and the need for optimized dosing to account for inter-subject variability in mucosal permeability.^[75]^[76]

Vaccines and Other Uses

Sublingual vaccines target infectious diseases by inducing mucosal immunity through antigen uptake primarily by M-cells in the oral mucosa, which facilitate transport to underlying lymphoid tissues for immune activation.^[77] This process stimulates the production of secretory IgA antibodies at mucosal sites, providing localized protection against pathogens entering via respiratory or gastrointestinal routes, while also eliciting systemic responses including IgG and T-cell immunity.^[78] Adjuvants such as the cholera toxin B subunit enhance antigen uptake and immunogenicity by promoting dendritic cell maturation and cytokine release, improving overall vaccine efficacy without significant toxicity in preclinical models.^[77] Promising candidates include sublingual formulations for norovirus, where plant-based or recombinant subunit vaccines have demonstrated robust mucosal IgA responses and protection in murine challenge models, though human trials remain preclinical.^[79] For influenza, phase I and II trials of inactivated or live-attenuated sublingual vaccines, such as quadrivalent formulations with novel adjuvants like ND002, have shown safety and immunogenicity, with seroconversion rates of approximately 60-70% for hemagglutinin-specific antibodies in healthy adults, comparable to intramuscular routes but with added mucosal benefits; as of 2025, phase II trials continue to evaluate efficacy.^[80] These trials highlight sublingual delivery's potential for annual influenza prophylaxis, inducing both local IgA in respiratory mucosa and systemic neutralizing antibodies.^[78] Recent advancements include sublingual COVID-19 boosters evaluated in 2023-2025 studies, such as protein-based formulations with receptor-binding domain antigen and poly(I:C) adjuvant, which elicited strong secretory IgA in saliva and serum IgG in non-human primates, supporting mucosal barrier enhancement against variants.^[81] For pediatric applications, oral rotavirus vaccines administered as drops have shown high efficacy in preventing severe gastroenteritis, with two-dose regimens achieving over 85% protection in infants starting at 6 weeks of age.^[82] Overall, sublingual vaccines demonstrate efficacy comparable to oral routes in mucosal protection but often yield superior systemic responses due to direct lymphatic drainage, though multi-dose regimens face adherence challenges in outpatient settings.^[83] Beyond vaccines, sublingual administration is utilized for various therapeutic applications, including antiemetics like ondansetron, which is delivered via orally disintegrating tablets to rapidly alleviate nausea and vomiting associated with chemotherapy, surgery, or gastroenteritis, achieving peak plasma levels within 30 minutes for quick onset.^[84] In hormone replacement therapy, sublingual estradiol effectively manages menopausal symptoms such as hot flashes and vaginal atrophy by providing bioidentical estrogen with high bioavailability, bypassing first-pass metabolism to maintain steady levels and reduce vasomotor symptoms in postmenopausal women.^[85]

References

[1]
Sublingual and Buccal Delivery: A Historical and Scientific Prescriptive
Aug 20, 2025 · In this review, our intention was to shed some light on the history of sublingual and buccal delivery over the past 75 years.
[2]
Drug Absorption - Clinical Pharmacology - Merck Manuals
A drug placed between the gums and cheek (buccal administration) or under the tongue (sublingual administration) is retained longer, enhancing absorption. The ...
[3]
Medication Routes of Administration - StatPearls - NCBI Bookshelf
A sublingual or buccal route is another form of the enteral route of medication administration that offers the benefit of bypassing the first-pass effect.
[4]
Sublingual drug delivery - PubMed
The sublingual route is one of the early modes of administration for systemic drug delivery. This route avoids first-pass metabolism and affords quick drug ...Missing: definition mechanism
[5]
Advances in Nanoparticulate Drug Delivery Approaches for ... - NIH
For sublingual and buccal administration, this means that drugs with a high pKa value are preferred due to the relatively neutral pH of the saliva.Table 1 · Nanoparticulate Drug... · Sublingual And Buccal...
[6]
(PDF) Sublingual route of drug administration in unani medicine
Sep 4, 2019 · The sublingual tablet or pill is one of the dosage forms used for the management of various emergency conditions like ischaemic heart diseases, hypertension, ...
[7]
[PDF] Advancement In Buccal And Sublingual Drug Delivery - IJCRT.org
Aug 8, 2024 · 1.2 Historical Background The use of buccal and sublingual routes can be traced back to ancient medicine, where substances were placed in ...
[8]
Nitrates and Nitrites in the Treatment of Ischemic Cardiac Disease
Sir Thomas Lauder Brunton first used amyl nitrite in the treatment of angina pectoris in 1867 [3]. Asa medical student, Brunton had became aware of prior ...
[9]
William Murrell and nitroglycerin - Hektoen International
Dec 7, 2023 · Born in London in 1853, William Murrell was the first to use nitroglycerin in the treatment of angina pectoris.Missing: sublingual | Show results with:sublingual
[10]
Nitroglycerin | Circulation - American Heart Association Journals
Newer drugs quickly replace older remedies. This has not been the case with nitroglycerin, now in continuous medical use for more than a century.
[11]
Efficacy of Grass Pollen Allergen Sublingual Immunotherapy Tablets ...
On April 1, 2014, the US Food and Drug Administration (FDA) announced approval of the 5–grass pollen sublingual tablet (Oralair; Stallergenes), followed by ...
[12]
Psychedelic Medicine Company Approved To Study Sublingual ...
May 20, 2021 · Cybin will launch a phase two clinical trial on its sublingual formulation of psilocybin, the psychedelic compound found in “magic mushrooms”, for patients ...
[13]
Apomorphine Sublingual: MedlinePlus Drug Information
Sep 15, 2025 · Drink water to moisten your mouth. · Open the pouch using the wing tabs. · Hold apomorphine sublingual film between your fingers by the outside ...Missing: procedure | Show results with:procedure
[14]
[PDF] SUBOXONE sublingual film - accessdata.fda.gov
SUBOXONE sublingual film should NOT be chewed, swallowed, or moved after placement. Proper administration technique should be demonstrated to the patient.Missing: procedure instructions
[15]
About Sublingual and Buccal Medication Administration - Healthline
Jun 6, 2017 · Sublingual administration involves placing a drug under your tongue to dissolve and absorb into your blood through the tissue there.
[16]
Sublingual Administration Guide: Examples and Definition - GoodRx
### General Best Practices for Sublingual Administration
[17]
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022410s000lbl.pdf
[18]
Acceptability of a Sublingual Drug Formulation for Respiratory Tract ...
Feb 23, 2021 · 50-mg PMBL sublingual tablets were classified as “positively accepted” in children aged 3 to 5 years on all three days of evaluation.
[19]
Considerations in Developing Sublingual Tablets—An Overview
Nov 2, 2014 · Sublingual administration of furosemide was shown to offer a therapeutic advantage over the oral route of administration (14). Oromucosal ...
[20]
Sublingual and Buccal Delivery: A Historical and Scientific Prescriptive
The various dosage forms—solid (e.g., tablets, films, and lozenges), liquid (e.g., sprays and oral drops), and semi-solid (e.g., gels)—are formulated to ...
[21]
Nitroglycerin - StatPearls - NCBI Bookshelf
Nitroglycerin is a vasodilatory drug used primarily to provide relief from anginal chest pain. It is currently FDA approved for the acute relief of an attack.Missing: early | Show results with:early
[22]
Orally dissolving strips: A new approach to oral drug delivery system
ADVANTAGES OF FAST DISSOLVING FILMS[9] · Convenient dosing. · No water needed. · No risk of chocking. · Taste masking. · Enhanced stability. · Improved patient ...
[23]
Sublingual Immunotherapy (SLIT) - Cleveland Clinic
Nov 14, 2023 · Sublingual immunotherapy (SLIT) is an allergy treatment that works by dissolving tablets or liquid under your tongue every day.
[24]
Development of Sedative Dexmedetomidine Sublingual In Situ Gels
Jan 18, 2022 · In this study, DEX sublingual in situ gels were developed and assessed for their pH, gelling capacity, viscosity, mucoadhesion and in vitro drug release.
[25]
Fast disintegrating tablets: Opportunity in drug delivery system - NIH
The time for disintegration of ODTs is generally <1 minute and actual disintegration time that patient can experience ranges from 5 to 30 seconds. The standard ...<|control11|><|separator|>
[26]
Transmucosal drug administration as an alternative route in ...
Nov 1, 2020 · The pH of the saliva plays an important role in keeping a balanced microbiota, and is maintained at around 5.5–7 [83]. Like other mucosal ...
[27]
Sublingual permeability of model drugs in New Zealand White Rabbits
Jan 5, 2025 · AUCIV and AUCsublingual are the areas under the curve following intravenous administration and sublingual administration, respectively. Dose ...<|separator|>
[28]
Microenvironmental pH Modification in Buccal/Sublingual Dosage ...
Feb 14, 2023 · This review aims to provide a short introduction to the pH M modification concept in buccal/sublingual dosage forms, the properties of saliva related to pH M ...
[29]
Bioavailability of sublingual buprenorphine - PubMed - NIH
Study results indicate that bioavailability of sublingual buprenorphine is approximately 30%. Sublingual exposure times between 3 and 5 minutes produce ...
[30]
Unusual Route of Buprenorphine Administration - PubMed Central
It has been reported that sublingual buprenorphine hydrochloride tablets have remarkable bioavailability (30%–50% of the intravenous route) and a prolonged ...
[31]
Pharmacokinetics and pharmacodynamics of sublingual microdosed ...
Apr 18, 2025 · We demonstrate that a one-compartment model was found to best describe the pharmacokinetics of microdosed sublingual LSD, consistent with ...Missing: blotter | Show results with:blotter
[32]
New company to put psilocybin on dissolvable sublingual strips to ...
Aug 13, 2020 · A 25mg psilocybin pill has become the unofficial standard for a therapeutic dose in clinical research and has been shown to be effective in ...
[33]
sublingual drug delivery: an indication of potential alternative route
Nov 17, 2017 · Drugs that are given sublingually reach directly in to the systemic circulation through the ventral surface of the tongue and floor of the mouth ...Missing: ancient herbal<|separator|>
[34]
Buprenorphine: clinical pharmacokinetics in the treatment of opioid ...
Buprenorphine undergoes extensive first-pass metabolism and therefore has very low oral bioavailability; however, its bioavailability sublingually is extensive ...
[35]
Buprenorphine vs methadone treatment: A review of evidence in ...
In this article we compare the advantages and disadvantages of the use methadone and buprenorphine for the treatment of opioid addiction from both a developed ...<|separator|>
[36]
Safety, effectiveness and tolerability of sublingual ketamine in ... - NIH
Sep 28, 2022 · This study demonstrates that SL ketamine is a novel, safe, and effective treatment for TRD and treatment-resistant anxiety.Missing: onset | Show results with:onset
[37]
Guidelines for ketamine use in clinical psychiatry practice - PMC
May 10, 2024 · This review of the evidence supports the rapid-onset efficacy (within 1–2 days) of esketamine and ketamine in TRD, which is best established for ...<|separator|>
[38]
Buprenorphine/naloxone (oromucosal route, sublingual route)
Buprenorphine and naloxone sublingual tablet is used to treat opioid (narcotic) dependence or addiction.Missing: aversion | Show results with:aversion
[39]
MDMA and MDMA-Assisted Therapy | American Journal of Psychiatry
Dec 20, 2024 · A considerable body of preliminary evidence suggests that MDMA-AT delivered in a controlled clinical setting is a safe and efficacious treatment for PTSD.
[40]
Retention and dropout from sublingual and extended-release ...
Feb 27, 2025 · This study evaluates retention and dropout probabilities between sublingual buprenorphine (SL-BUP) and extended-release buprenorphine (XR-BUP)
[41]
Sublingual Immunotherapy - Allergy Drops - Johns Hopkins Medicine
Sublingual immunotherapy can help address a variety of airborne allergens, including pet dander, tree and grass pollen, and molds. What is sublingual ...
[42]
Sublingual immunotherapy for allergic rhinitis - PubMed
There were six trials of SLIT for house dust mite allergy, five for grass pollen, five for parietaria, two for olive and one each for, ragweed, cat, tree and ...
[43]
Duration of Allergen Immunotherapy for Long-Term Efficacy in ... - NIH
Aug 31, 2018 · These three studies provide robust evidence for induction of lasting tolerance after 3 years of grass pollen SLIT [9, 17, 18, 30–33].
[44]
Sublingual Immunotherapy Chicago | SLIT Chicago
For most patients, SLIT treatment lasts between 3-5 years. SLIT takes so long to ensure patients achieve optimal allergy relief. After establishing the correct ...
[45]
How Sublingual Allergen Administration Heals Allergic Diseases ...
Feb 2, 2021 · A decrease in the IgE/IgG4 ratio was observed following SLIT, which was correlated with the suppression of allergen-induced skin reactions and/ ...
[46]
Sublingual immunotherapy induces IL-10–producing T regulatory ...
Conclusion. SLIT induces regulatory T-cell suppression through IL-10 during the early phase and specific nonreactivity and immune deviation of allergen-specific ...
[47]
Update on Immune Mechanisms Associated with Sublingual ...
The induction of CD4+ regulatory T cells and blocking anti-inflammatory IgGs or IgAs are considered important for tolerance induction after SLIT. Specific ...Antigen-Presenting Cells · Lymphoid Cells · Oral Lymphoid Organs
[48]
Efficacy and safety of Sublingual immunotherapy for allergic rhinitis
Sep 11, 2025 · Current evidence demonstrates that Sublingual Immunotherapy exhibits favorable efficacy in improving symptom scores and medication use for ...<|separator|>
[49]
An Alternative Treatment for Allergies at Their Root Causes
Oct 10, 2025 · Several studies confirm that SLIT can significantly reduce allergy symptoms, from 30-70% within 6-12 months, and provide long-term results after ...<|separator|>
[50]
Choosing the optimal dose in sublingual immunotherapy - NIH
Dec 23, 2015 · The approved titration of OA varies with country and/or patient age, but typically involves a 3-day dose-escalation from 100 to 300 IR per day, ...
[51]
Choosing the optimal dose in sublingual immunotherapy
Dec 23, 2015 · The conventional dosing scheme for 300 IR SLIT drops (Staloral®) consists of two phases: a titration phase with an escalation of the dose and a ...
[52]
ALK announces FDA approval for Merck's grass sublingual allergy ...
Apr 14, 2014 · GRAZAX® was approved in Europe in 2006 and is currently marketed in 16 European countries. GRAZAX® is licensed to Merck (known as MSD outside ...
[53]
GRAZAX®: a sublingual immunotherapy vaccine for Hay fever ... - NIH
GRAZAX is the first global allergy vaccine developed in compliance with the new legal environment and is thus a reference for developing new allergy vaccines.
[54]
Anaphylaxis is rare with sublingual immunotherapy tablets
Nov 14, 2023 · Thus, the overall proportion of treatment-related anaphylaxis was 0.02% (2 cases/8200 subjects) with SLIT-tablet and 0.01% (1 case/7033 subjects) ...
[55]
Efficacy and safety of sublingual versus subcutaneous ... - Frontiers
Sublingual immunotherapy (SLIT) for house dust mites does not prevent new allergen sensitization and bronchial hyper-responsiveness in allergic rhinitis ...
[56]
Allergen immunotherapy: an updated review of safety - PMC - NIH
The risk of systemic reactions with subcutaneous immunotherapy remains quite low, but near-fatal and fatal anaphylaxis does occur, requiring physicians to ...Missing: 0.8%
[57]
FDA OKs Dust Mite Allergy Drug for Young Kids - MedPage Today
Feb 28, 2025 · The FDA expanded the approval of a sublingual immunotherapy (SLIT; Odactra) for treating house dust mite allergies in young children.
[58]
FDA expands label for Odactra dust mite allergen tablet to children 5 ...
Feb 28, 2025 · The expanded indication now includes children aged 5 through 11 years, in addition to patients aged 12 to 65 years.Missing: multi- | Show results with:multi-<|control11|><|separator|>
[59]
The KAAACI Guidelines for Sublingual Immunotherapy
Oct 25, 2023 · SLIT using multi-allergen extracts may not be effective due to the limited capacity for absorption of the sublingual mucosa, which is ...
[60]
Oral delivery of protein and peptide drugs: from non-specific ...
This review summarizes the main challenges for oral protein and peptide drugs delivery and highlights the advanced formulation strategies to improve their oral ...
[61]
https://pmc.ncbi.nlm.nih.gov/articles/PMC5644500/
[62]
Desmopressin 120 micrograms Sublingual Tablets - (emc) | 14855
The overall mean systemic bioavailability of desmopressin administered sublingually at doses of 200, 400 and 800 micrograms is 0.25% with a 95% confidence ...Missing: absolute | Show results with:absolute
[63]
Insulin-loaded alginic acid nanoparticles for sublingual delivery
Jun 5, 2014 · Sublingually delivered NPs with nicotinamide exhibited high pharmacological availability (>100%) and bioavailability (>80%) at a dose of 5 IU/kg ...Missing: trials | Show results with:trials
[64]
[PDF] Product information for AusPAR - Nocdurna - Desmopressin - Ferring
Nov 27, 2017 · Absorption. The overall mean absolute bioavailability of desmopressin administered sublingually in doses of 200, 400 and 800 micrograms is 0.25% ...<|control11|><|separator|>
[65]
Galmed Signed Term Sheet for the Development of Novel ...
Apr 28, 2025 · Sublingual administration offers a potential alternative to both the approved injectable semaglutide (Ozempic and Wegovy) and the oral form ( ...
[66]
[PDF] Recent insights, challenges and emerging trends in sublingual drug ...
The article illustrates marketed products and current clinical applications, offers insights into future prospects for sublingual delivery, and serves as a ...<|control11|><|separator|>
[67]
Basics and recent advances in peptide and protein drug delivery - NIH
This review discusses oral and transdermal peptide drug delivery, focusing on barriers and solutions to absorption and stability issues.
[68]
Biopharmaceutics and clinical outcomes of emerging dosage forms ...
The bioavailability of insulin from the transdermal patches was found to be in the domain of 21.5% based on serum level and 39.5% based on the pharmacodynamic ...Missing: sublingual | Show results with:sublingual
[69]
Challenges and opportunities in delivering oral peptides and proteins
Jul 17, 2023 · Areas covered: This review describes the barriers to oral delivery of peptides and complex proteins, current oral delivery strategies utilized ...
[70]
Buccal and Sublingual Vaccines: A Review on Oral Mucosal ...
Oct 14, 2021 · This turns out to be an important advantage in terms of the safety of the sublingual route over other conventionally used routes. In addition, ...2. Mucosal Immune System · 3.2. Microneedle Array · 3.3. Mucosal Adjuvants<|control11|><|separator|>
[71]
Sublingual Delivery of Vaccines for the Induction of Mucosal Immunity
In these studies, sublingual immunization has been shown to be safe and highly effective in generating robust immune responses against the administered antigen.
[72]
Recent Advancements in Non-Invasive Vaccination Strategies - MDPI
This adhesion prolongs the retention of antigens at their site of administration, increases the chances of uptake by mucosal immune cells like M cells and ...
[73]
Study Details | NCT02955030 - ClinicalTrials.gov
The purpose of this study is to evaluate the safety and immunogenicity of a sublingual administration of NSV0001 in healthy male volunteers. Detailed ...
[74]
SARS-CoV-2 sublingual vaccine with RBD antigen and poly(I:C ...
These indicated that the sublingual vaccine stimulated mucosal immune response to produce antigen-specific secretory IgA antibodies in pituita and/or saliva.
[75]
Rotavirus Vaccination - CDC
Jul 19, 2024 · Both available rotavirus vaccines are given by putting drops in the infant's mouth. Your child's doctor can help you choose which rotavirus ...
[76]
Recent Advancements in Non-Invasive Vaccination Strategies - PMC
Sep 16, 2025 · This review aims to comprehensively discuss recent advancements in oral, intranasal, microneedle, buccal, sublingual, and vaginal vaccinations ...
[77]
Ondansetron (oral route, oromucosal route) - Side effects & dosage
Ondansetron is used to prevent nausea and vomiting that is caused by cancer medicines (chemotherapy) or radiation therapy.
[78]
The effectiveness of sublingual and topical compounded ... - PubMed
Compounded sublingual bioidentical hormone replacement therapy is effective in reducing vasomotor, mood, and quality-of-life symptoms experienced in post- ...